Radiation-induced Toxicity of the Heart
Launched by TECHNISCHE UNIVERSITÄT DRESDEN · May 15, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how radiation treatment for certain types of cancer—specifically non-small cell lung cancer, esophageal cancer, and breast cancer in women—can affect the heart. Researchers want to find ways to predict if patients might experience heart problems after receiving radiation or chemotherapy. They will be studying different tests, including blood tests and imaging scans, to see if they can identify patients at risk for these side effects.
To participate in this trial, patients need to be at least 18 years old and be diagnosed with one of the specified cancers that require curative treatment. They must also be able to give their consent to join the study. Unfortunately, those who cannot consent, are pregnant, or have certain medical devices or health issues will not be eligible. Participants can expect to undergo various tests to help researchers understand better how to protect the heart during cancer treatment. This study is important because it aims to improve the quality of life for cancer patients by minimizing heart-related side effects from their treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years old or older
- • Patient's consent and written consent is available
- • Patients with the non-small cell lung cancer or esophageal cancer or breast cancer who have an indication for intended curative radio(chemo)therapy (in the case of breast cancer inclusion of female patients only)
- Exclusion Criteria:
- • Patients who are not capable of giving consent
- • Pregnant women
- • Patients with contraindications for MRI examinations (pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, permanent make-up, metal splinters or osseosynthetic implants)
- • Patients with insufficient kidney function (glomerular filtration rate (GFR) of less than 30 ml/min)
- • Patients with the aforementioned tumour entities for whom a palliative indication exists
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dresden, , Germany
Patients applied
Trial Officials
Esther G. C. Troost, Prof. Dr. med. Dr.
Principal Investigator
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported